Coldstream Capital Management Inc. Acquires 402 Shares of Align Technology, Inc. $ALGN

Coldstream Capital Management Inc. boosted its stake in shares of Align Technology, Inc. (NASDAQ:ALGN) by 22.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,228 shares of the medical equipment provider’s stock after buying an additional 402 shares during the period. Coldstream Capital Management Inc.’s holdings in Align Technology were worth $422,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of ALGN. Vanguard Group Inc. raised its position in shares of Align Technology by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,441,592 shares of the medical equipment provider’s stock worth $1,341,031,000 after acquiring an additional 185,187 shares in the last quarter. Invesco Ltd. grew its stake in Align Technology by 12.7% in the first quarter. Invesco Ltd. now owns 1,219,715 shares of the medical equipment provider’s stock valued at $193,764,000 after purchasing an additional 137,553 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Align Technology by 32.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock worth $132,221,000 after purchasing an additional 202,616 shares in the last quarter. Navera Investment Management Ltd. raised its holdings in Align Technology by 3.0% in the second quarter. Navera Investment Management Ltd. now owns 787,559 shares of the medical equipment provider’s stock worth $149,126,000 after purchasing an additional 23,080 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Align Technology by 0.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 736,635 shares of the medical equipment provider’s stock valued at $117,022,000 after buying an additional 4,789 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.

Align Technology Price Performance

Shares of ALGN opened at $147.23 on Friday. The company’s fifty day moving average price is $134.14 and its 200-day moving average price is $156.95. Align Technology, Inc. has a 1-year low of $122.00 and a 1-year high of $246.19. The firm has a market capitalization of $10.56 billion, a PE ratio of 28.53, a price-to-earnings-growth ratio of 1.49 and a beta of 1.84.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $2.61 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.23. The company had revenue of $995.69 million during the quarter, compared to analysts’ expectations of $980.75 million. Align Technology had a return on equity of 14.06% and a net margin of 9.50%.The firm’s revenue was up 1.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.35 EPS. Align Technology has set its Q4 2025 guidance at EPS. As a group, research analysts anticipate that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Align Technology announced that its Board of Directors has approved a share buyback plan on Tuesday, August 5th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ALGN. HSBC lifted their price objective on shares of Align Technology from $140.00 to $150.00 in a research report on Friday, October 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $200.00 price target (up from $190.00) on shares of Align Technology in a report on Thursday, October 30th. Morgan Stanley increased their price objective on Align Technology from $142.00 to $154.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Stifel Nicolaus set a $200.00 target price on Align Technology in a research note on Thursday, October 30th. Finally, Wells Fargo & Company reduced their target price on Align Technology from $199.00 to $181.00 and set an “overweight” rating on the stock in a research report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $175.45.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.